MIRA PHARMACEUTICALS, INC. COMMON STOCK
NASDAQ: MIRA (MIRA Pharmaceuticals, Inc.)
Last update: yesterday, 9:55AM0.660
0.01 (1.77%)
AIStockmoo Score
| Value 30% | 0.0 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | 0.0 |
| Timing 30% | 2.8 |
| AI Technical info | NA |
| Technical Oscillators info | 3.0 |
| Technical Moving Averages info | 2.5 |
| Candle Patterns info | NA |
| Sentiment 20% | 0.0 |
| Analyst Consensus info | 0.0 |
| News Mood info | NA |
| Smart Money 20% | 0.8 |
| Insider Activity info | NA |
| Institutional Flow info | 2.1 |
| Short Interest info | -2.2 |
| Environment | ×1.00 |
| Macro Environment info | -1.3 |
| Sector vs Market (6M) | +10.3% |
| Pillar Agreement | ×1.25 |
| Not in score | |
| Price Volatility info | 1.4 |
| Final Score | 1.26 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - General (US) | Mixed | Bullish |
| Drug Manufacturers - General (Global) | Mixed | Bullish | |
| Stock | MIRA Pharmaceuticals, Inc. | Mixed | Mixed |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| MIRA | - | - | - | 3.34 |
| SNY | - | 5.01% | - | 1.40 |
| GILD | - | 1.93% | - | 16.00 |
| AMGN | - | 2.14% | - | 17.60 |
| GRFS | - | 1.07% | - | 0.900 |
| BIIB | - | - | - | 1.94 |
Select this tab to load the latest available analysis.
|
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Investment Style | Small Growth |
| % Held by Insiders | 19.68% |
| % Held by Institutions | 5.60% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Cross Staff Investments Inc | 30 Sep 2026 | 359,401 |
| First American Bank | 30 Sep 2026 | 60,000 |
No data within this time range.
Institutions
Institutional ownership: 7.43%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 8 | 673,009 |
| Decreased | 12 | 102,950 |
| New | 2 | 20,841 |
| Sold out | 6 | 37,839 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 282,319 | 1.4 |
| 15 Oct 2026 | 349,714 | 2.4 |
| 30 Sep 2026 | 408,844 | 2.4 |
| 15 Sep 2026 | 447,832 | 1.0 |
| 31 Aug 2026 | 205,296 | 4.1 |
| 14 Aug 2026 | 211,083 | 1.5 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 29 Oct 2026 | Yahoo Finance |
Inside Deep Principle: The AI That Runs Its Own Chemistry Experiments to Discover New Materials
HANGZHOU, CHINA / ACCESS Newswire / October 29, 2026 / Inside a lab in Hangzhou, an AI system named Mira recently pushed a single-step reaction's selectivity from 51.82% to 85% in three months, without a chemist manually running the experiments. |
| 29 Oct 2026 | Yahoo Finance |
MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide
SKNY-1's Weight Reduction Without Significant Changes in Food Consumption Suggests a Potential Role for Energy Expenditure, Contrasting With Semaglutide's Initial Food-Intake Suppression and Significant Post-Treatment Increase MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc.… |
| 22 Oct 2026 | Yahoo Finance |
MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study
Positive IND-Enabling Proof-of-Concept Study Demonstrates Sustained Efficacy Without Observed Tolerance, Reduced Inflammation-Associated Swelling, and Favorable TolerabilityMIAMI, Oct. 22, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage… |
| 21 Oct 2026 | Yahoo Finance |
Modera Launches AI-Powered Platform Mira to Support Tailored Financial Advice for Clients
Modera Wealth Management, LLC ("Modera"), a fee-only wealth management firm serving individuals, families, business owners, and nonprofit organizations, today announced it has launched Mira, a proprietary agentic AI-powered platform. Mira is designed to harmonize data and support tailored financial… |
| 17 Sep 2026 | Yahoo Finance |
MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
Protocol Submitted for IRB Review at a Leading Cancer Research Institution, Advancing the Study Toward Site InitiationMIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral… |
| 16 Sep 2026 | Yahoo Finance |
Copper Giant Identifies Thirteen Targets Beyond the Mocoa Resource and Its Interpreted Extensions
Copper Giant Resources Corp. ("Copper Giant" or the "Company") (TSXV: CGNT) (OTCQX: CGNRF) (FRA: 29H0) today reports the results of an independent geophysical modelling and predictive targeting study completed by Mira Geoscience Ltd. ("Mira") over its Mocoa copper-molybdenum porphyry project in… |
| 01 Sep 2026 | Yahoo Finance |
Landmark 2026 Clinical Study Validates At-Home Quantitative Multi-Hormone Monitoring Against Ultrasound Gold Standard
A landmark clinical study published in Reproductive BioMedicine Online (Bouchard et al., 2026) provides strong diagnostic accuracy validation for at-home quantitative multi-hormone tracking, establishing a major milestone in reproductive healthcare and FemTech. |
| 01 Sep 2026 | Yahoo Finance |
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
Positive Toxicology Results From 7-Day Rat and Dog Studies Characterize Tolerability and Inform Dose Selection for Next Phase of IND-Enabling Program, Targeting Q1 2027 IND SubmissionMIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a… |
Recent Signals candle patterns and EMA crosses
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |